Prednisone
- Generic Name
- Prednisone
- Brand Names
- Deltasone, Rayos, Winpred
- Drug Type
- Small Molecule
- Chemical Formula
- C21H26O5
- CAS Number
- 53-03-2
- Unique Ingredient Identifier
- VB0R961HZT
- Background
A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.
Prednisone was granted FDA approval on 21 February 1955.
- Indication
Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.
- Associated Conditions
- Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis
- Associated Therapies
- Palliative Treatment
VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2023-05-18
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT04433156
- Locations
- 🇨🇳
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, Zhengzhou, Henan, China
Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement
- Conditions
- Interventions
- First Posted Date
- 2020-06-16
- Last Posted Date
- 2020-06-16
- Target Recruit Count
- 81
- Registration Number
- NCT04432714
- Locations
- 🇨🇳
The first Affiliated Hospital Of Nanjing Medical University(JiangSu Province Hospital), Nanjing, Jiangsu, China
Phase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE)
- Conditions
- Interventions
- First Posted Date
- 2020-06-02
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Prevail Therapeutics
- Target Recruit Count
- 15
- Registration Number
- NCT04411654
- Locations
- 🇬🇧
Manchester Centre for Genomic Medicine, 6th Floor, St Mary's Hospital, Oxford Road, Manchester, United Kingdom
🇺🇸UCSF Benioff Children's Hospital, 5700 Martin Luther King Jr Way, Oakland, California, United States
🇺🇸University of Minnesota Masonic Children's Hospital, 2450 Riverside Avenue, Minneapolis, Minnesota, United States
Prednisolone Treatment in Acute Interstitial Nephritis
- First Posted Date
- 2020-05-06
- Last Posted Date
- 2020-12-30
- Lead Sponsor
- Region MidtJylland Denmark
- Target Recruit Count
- 110
- Registration Number
- NCT04376216
- Locations
- 🇩🇰
Godstrup Hospital, Herning, Denmark
Efficacy and Safety of Corticosteroids in Oxygen-dependent Patients With COVID-19 Pneumonia
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2021-05-12
- Lead Sponsor
- University Hospital, Tours
- Registration Number
- NCT04359511
Effect of Glucocorticoid on Exogenous Insulin Antibody Syndrome
- First Posted Date
- 2020-04-22
- Last Posted Date
- 2020-04-24
- Lead Sponsor
- chenfengling
- Target Recruit Count
- 20
- Registration Number
- NCT04357392
Neoadjuvant Therapy of Abiraterone Plus ADT for High Risk Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-04-22
- Last Posted Date
- 2022-12-16
- Target Recruit Count
- 75
- Registration Number
- NCT04356430
- Locations
- 🇨🇳
Department of Urology, Drum Tower Hospital, Medical School of Nanjing University, Institute of Urology, Nanjing University, Nanjing, Jiangsu, China
Corticosteroids During Covid-19 Viral Pneumonia Related to SARS-Cov-2 Infection
- Conditions
- Interventions
- First Posted Date
- 2020-04-14
- Last Posted Date
- 2020-10-26
- Lead Sponsor
- Hospices Civils de Lyon
- Target Recruit Count
- 11
- Registration Number
- NCT04344288
- Locations
- 🇫🇷
Médipôle, Villeurbanne, France
🇫🇷Hôpital Pneumologique et Cardiovasculaire Louis Pradel, Bron, France
🇫🇷Hôpital Edouard Herriot, Lyon, France
Cemiplimab in AlloSCT/SOT Recipients With CSCC
- Conditions
- Interventions
- First Posted Date
- 2020-04-08
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 12
- Registration Number
- NCT04339062
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Parsaclisib With or Without Polatuzumab Vedotin Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma
- Conditions
- Ann Arbor Stage II Diffuse Large B-Cell LymphomaAnn Arbor Stage II Follicular LymphomaAnn Arbor Stage II Marginal Zone LymphomaAnn Arbor Stage III Diffuse Large B-Cell LymphomaAnn Arbor Stage III Follicular LymphomaAnn Arbor Stage III Marginal Zone LymphomaAnn Arbor Stage IV Diffuse Large B-Cell LymphomaAnn Arbor Stage IV Follicular LymphomaAnn Arbor Stage IV Marginal Zone LymphomaDiffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2020-03-27
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 50
- Registration Number
- NCT04323956
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸Mayo Clinic in Rochester, Rochester, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.